Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 9191 5r 5?
Displaying drugs 6626 - 6650 of 8166 in total
Investigational
Investigational
Experimental
Matched Iupac: … (2S)-2-[(2S)-2-{[hydroxy({[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy})phosphoryl]amino} …
Experimental
Matched Iupac: … (2R,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R,6R)-6-[(6-cyclohexylhexyl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan- …
Experimental
Matched Iupac: … [(5S)-5-amino-5-carboxypentyl]trihydroxyboranuide …
Experimental
Matched Name: … (R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide …
Experimental
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
Experimental
Matched Name: … (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium …
Edralbrutinib is an orally available small molecule inhibitor of Bruton's tyrosine kinase.
Investigational
HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Investigational
Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).
Investigational
An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.
Experimental
Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.
Experimental
Investigational
Investigational
Investigational
Experimental
Matched Iupac: … 3-oxo-1,3-dihydro-2-benzofuran-1-yl (2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo- …
Sulopenem is under investigation in clinical trial NCT03357614 (Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults).
Investigational
Matched Iupac: … (1R,3S)-3-{[(5R,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl] …
Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Withdrawn
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.
Investigational
Displaying drugs 6626 - 6650 of 8166 in total